TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET

Rhea-AI Summary

TYME Technologies, Inc. (NASDAQ: TYME) will disclose its third quarter 2022 financial results on February 11, 2022, at 8:30 AM ET. CEO Richie Cunningham and CFO Frank Porfido will lead a conference call and webcast, which is available on the Investors page of the TYME website. Participants can submit questions before the call, with a deadline set for 5:00 PM ET on February 7, 2022. The company focuses on cancer metabolism-based therapies for a range of cancers.

BEDMINSTER, N.J.--(BUSINESS WIRE)-- TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET.

Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows:

Date:				Friday, February 11, 2022
Time:				8:30 AM ET
Toll-free (U.S.)				(866) 601-3896
International				(636) 812-6499
Conference ID				1286376

The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.

Following the Company’s presentation, there will be a Q&A session. Management will address both live questions and those submitted in advance via email to lwilson@insitecony.com. The deadline to submit questions for the conference call is 5:00 PM ET on February 7, 2022.

About TYME Technologies, Inc.
TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to cause cancer cell death.

The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline.

For more information about the Company, visit www.tymeinc.com and connect on Facebook, LinkedIn, and Twitter.

Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form

10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 10, 2021, as well as subsequent reports and filings from time to time with the SEC.

The information contained in this press release is as of the release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005991/en/

INVESTOR AND MEDIA:

In-Site Communications

Lisa M. Wilson

T: 212-452-2793

E: lwilson@insitecony.com

Source: TYME Technologies, Inc.

FAQ

When will TYME Technologies report its Q3 2022 financial results?

TYME Technologies will report its third quarter 2022 financial results on February 11, 2022, at 8:30 AM ET.

Who will host the TYME Technologies Q3 2022 earnings call?

The Q3 2022 earnings call will be hosted by CEO Richie Cunningham and CFO Frank Porfido.

How can I access the TYME Technologies conference call?

The conference call can be accessed via the webcast available on the Investors page of the TYME website.

What is the deadline to submit questions for the TYME Technologies earnings call?

The deadline to submit questions for the conference call is 5:00 PM ET on February 7, 2022.

What therapies is TYME Technologies developing?

TYME Technologies is developing cancer metabolism-based therapies (CMBTs™) for various solid tumors and hematologic cancers.